This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Smith, D., Newlands, E., Spruyt, O. et al. Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy. Br J Cancer 61, 323–324 (1990). https://doi.org/10.1038/bjc.1990.62
Issue Date:
DOI: https://doi.org/10.1038/bjc.1990.62
This article is cited by
-
Management der Chemotherapie-induzierten Emesis: Was ist Standard nach 20 Jahren klinischer Forschung?
Medizinische Klinik (1998)
-
Antiemetics in cancer chemotherapy: historical perspective and current state of the art
Supportive Care in Cancer (1994)
-
Antiemetics in children receiving cancer chemotherapy
Supportive Care in Cancer (1994)
-
Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient
Breast Cancer Research and Treatment (1991)
-
5-Hydroxytryptamine (serotonin) subtype 3 antagonists, a major step in prophylaxis and control of cytostatic and radiation-induced emesis
Journal of Cancer Research and Clinical Oncology (1991)